Cadila Healthcare had a dream three-year run, what with the company managing to reach the billion-dollar revenue mark last year. While to some extent the bettering business fundamentals — helped by the increasing demand for generics in developed markets and the strengthening demand trends in the domestic markets would have helped, credit must go to Cadila's well-thought out growth strategy too.

Unlike some of its peers, Cadila side-stepped big ticket acquisitions as a part of its global growth strategy and instead focussed on smaller buys that gave it access to strategic markets. Joint ventures with established players — Nycomed, Hospira and Bayer — and licensing agreements with MNCs also helped it significantly.

Back home, portfolio expansion, new product launches, in-licensing arrangements, increased market penetrations by adding to its field force periodically and strong positioning in the Indian consumer wellness market helped Cadila chart an attractive growth trajectory.

In FY11, the company reported 25 per cent growth in sales to Rs 4,465 crore, driven by growth in both export as well as domestic formulations. Net profits for the year were up by 41 per cent to Rs 711 crore. The company now expects to grow, depending on the products, at an annual growth rate in the range of 20-30 per cent each year to reach the $3-billion target by 2015.

Read the rest of this article by Signing up for Portfolio.It's completely free!

What You'll Get


This article is closed for comments.
Please Email the Editor